Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277921 | 0.81 | LMNA (0.45) | TSHRCYP1A2LMNA | |
| SCHEMBL9768597 | 0.78 | CYP2C19 (0.45) | TSHRCYP1A2LMNA | |
| SCHEMBL1273487 | 0.78 | ALDH1A1 (0.41) | TSHRCYP1A2LMNATHRB | |
| SCHEMBL7795109 | 0.78 | LMNA (0.43) | TSHRCYP1A2LMNA | |
| SCHEMBL127102 | 0.78 | — | — | |
| SCHEMBL15902303 | 0.78 | LMNA (0.43) | TSHRCYP1A2LMNA | |
| SCHEMBL8090548 | 0.76 | ALDH1A1 (0.39) | TSHRCYP1A2LMNATHRB | |
| SCHEMBL8011003 | 0.76 | ALDH1A1 (0.39) | TSHRCYP1A2LMNATHRB | |
| SCHEMBL3954846 | 0.76 | ALDH1A1 (0.39) | TSHRCYP1A2LMNATHRB | |
| Ammonia Solution, Strong SCHEMBL21462229 | 0.76 | TSHR (0.48) | TSHRCYP1A2MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119782-A1 | METHOD FOR THE MANUFACTURE OF NEW AMINE | EVONIK OPERATIONS GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| WO-2025119782-A1 | METHOD FOR THE MANUFACTURE OF NEW AMINE | EVONIK OPERATIONS GMBH (DE) | 2025-06-12 | — | — | WO | disclosed |
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
| EP-3300157-A2 | NON-AQUEOUS ELECTROLYTE ADDITIVE, NON-AQUEOUS ELECTROLYTE CONTAINING SAME FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY | LG Chem, Ltd. (KR) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | PTH1R, CALCR, VDR | TSHR 13/4885CYP1A2 4787/4885MAPK1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.